CAMBRIDGE, Mass., April 8, 2025 – Prologue Medicines, a biotechnology company creating new medicines by unlocking the therapeutic potential of viral proteins, today announced the appointment of Raj Chopra, M.D., Ph.D., as Chief Scientific Officer. Dr. Chopra will lead the advancement of Prologue’s DELVE™ platform and the company’s pipeline targeting various diseases, including immunology, oncology and metabolic conditions.

"We are delighted to welcome Raj to Prologue’s executive team,” said Lovisa Afzelius, Ph.D., MBA, Co-Founder and CEO of Prologue and General Partner at Flagship Pioneering. "His rich experience in drug development will be instrumental as we continue to advance our platform and our pipeline of novel therapeutics. I am confident he will play a vital role in Prologue’s mission to leverage the millions of viral proteins with potential therapeutic applications.”

Dr. Chopra’s distinguished career spans both industry and academia. Most recently, he served as Chief Medical Officer of Marengo Therapeutics and Head of Oncology/Venture Partner at ATP (Apple Tree Partners). His previous roles include Corporate Vice President of Translational and Early Drug Development at Celgene and leadership positions in AstraZeneca’s Oncology Therapeutics group. Dr. Chopra also directed the Cancer Research UK Cancer Therapeutics Unit at the Institute of Cancer Research in London, leading one of the largest academic drug discovery groups globally. He trained in medicine at University College London, where he earned his M.D. and a Ph.D. in medicine, cell and molecular biology.

"I am impressed with the innovative platform Prologue has developed and its ability to both generate unique assets and identify novel targets, giving us full line of sight between the identification and development of a therapeutic asset,” said Dr. Chopra.  “I look forward to bringing my expertise in preclinical and early clinical development to collaborate with the talented team at Prologue to create powerful new medicines that will significantly impact patient care.”

About Prologue Medicines

Prologue Medicines is creating powerful new medicines by unlocking the therapeutic potential of viral proteins. Viral proteins have evolved with humans for millions of years and have been optimized to modulate human biology. Powered by the largest known database of viral protein structures, Prologue’s DELVE™ machine learning platform systematically identifies the proteins that precisely regulate human biology, uncovers new therapeutic targets and programs transformative features into novel therapeutics. Prologue was founded by Flagship Pioneering in 2021. ‍

Media Contact:

Morgan Warners
FGS Global
morgan.warners@fgsglobal.com 

Melanie West
FGS Global
melanie.west@fgsglobal.com